Specific character of anaerobic bacterial infections in patients treated in transplantation wards at one of the clinical hospitals in Warsaw.
Immunocompromised patients and patients undergoing invasive procedures are predisposed to bacterial infections, due to the possibility of micro-organism translocation from their physiological habitat. Infectious complications may occur both in the early and late post-transplantation periods. The purpose of this study was to evaluate the proportion as well as susceptibility profiles of obligatory anaerobes in the etiology of infections in patients hospitalized at transplantation wards of a large clinical hospital in Warsaw. A total of 104 strains of obligatory anaerobes derived from patients hospitalized in two transplantation clinics at a clinical hospital in Warsaw were evaluated. The strains were isolated from 87 clinical samples collected from 84 patients of two transplantation wards between 2007 and 2012. A total of 104 obligatory anaerobic bacterial strains were isolated and identified, with Gram-positive and Gram-negative bacteria constituting 60.6% and 39.4% of the isolates, respectively. Almost exclusively non-spore-forming anaerobes were detected in evaluated samples. The present study showed all isolated Gram-positive bacteria to be susceptible to ß-lactam antibiotics. Metronidazole-resistant bacteria were found among the genera Propionibacterium and Actinomyces. All Gram-negative rods were susceptible to imipenem and metronidazole. Among them, Bacteroides spp. and Parabacteroides distasonis showed resistance to penicillin G (100%). Because of their pathogenicity and altered antibiotic susceptibility profiles, the bacteria of the genera Bacteroides and Parabacteroides are of greatest clinical importance. Approximately 25% of isolates exhibit also resistance to clindamycin. Because of the growing rates of clindamycin resistance, the role of metronidazole in the treatment of Bacteroides spp. is of increasing importance.
Department of Medical Microbiology, Medical University of Warsaw, Warsaw, Poland.
M
M
Kierzkowska
Department of Medical Microbiology, Medical University of Warsaw, Warsaw, Poland.
A
A
Majewska
Department of Medical Microbiology, Medical University of Warsaw, Warsaw, Poland.
A
A
Sawicka-Grzelak
Department of Dental Microbiology, Medical University of Warsaw, Warsaw, Poland.
A
A
Mlynarczyk
Department of General and Transplantation Surgery, Transplantology Institute, Medical University of Warsaw, Warsaw, Poland.
A
A
Chmura
Department of Transplant Medicine and Nephrology, Transplantology Institute, Medical University of Warsaw, Warsaw, Poland.
M
M
Durlik
Department of Transplant Medicine and Nephrology, Transplantology Institute, Medical University of Warsaw, Warsaw, Poland.
D
D
Deborska-Materkowska
Department of Immunology, Transplantology and Internal Diseases, Transplantology Institute, Medical University of Warsaw, Warsaw, Poland.
L
L
Paczek
Department of Medical Microbiology, Medical University of Warsaw, Warsaw, Poland. Electronic address: grazyna.mlynarczyk@wum.edu.pl.
G
G
Mlynarczyk
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001421:Bacteria, Anaerobic / Q000302:isolation & purification; D001424:Bacterial Infections / Q000382:microbiology*; D006094:Gram-Positive Bacteria / Q000302:isolation & purification; D006801:Humans; D015378:Imipenem; D016867:Immunocompromised Host; D008795:Metronidazole; D008826:Microbial Sensitivity Tests; D011044:Poland; D047090:beta-Lactams / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D047090:beta-Lactams; D008795:Metronidazole; D015378:Imipenem